Ghrelin and Insulin Resistance
This trial is active, not recruiting.
|Conditions||obesity, insulin resistance, normal weight,healthy controls|
|Treatment||ghrelin infusion to assess effects on insulin sensitivity|
|Start date||August 2011|
|End date||December 2016|
|Trial size||20 participants|
|Trial identifier||NCT00884494, IRB#090362, NIH: RO1-DK070860-01S1|
Ghrelin, a hormone produced in the stomach that stimulates hunger and food intake, declines immediately after weight loss surgery. Some studies suggest that ghrelin may worsen an individual's ability to respond to insulin. The purpose of this study is to determine if the decline in ghrelin levels after weight loss surgery contributes to the improvement of insulin sensitivity.
Ghrelin infusion to assess effects on insulin sensitivity
Normal weight, healthy adults to act as controls
Evaluate the effect of ghrelin on insulin resistance in obese subject, as well as subjects in the immediate post-RYGB period.
time frame: 1 year
Male or female participants from 18 years up to 65 years old.
- Age 18-65
- BMI > 35 kg/m2
- Scheduled for bariatric surgery at Vanderbilt University Medical Center Inclusion for Control group:
- Age 18-65
- BMI < 30kg/m2
- Prior bariatric surgery
- Serum creatinine > 1/5 mg/dl
- Hepatic enzyme elevations > 2x upper limits of normal
- Current use of warfarin or clopidogrel
- Intercurrent infections
- Females with positive pregnancy test
- Abnormal ECG
|Official title||Role of Ghrelin in the Improvement of Insulin Resistance After Roux-en-Y Gastric Bypass Surgery|
|Principal investigator||Robyn Tamboli, PhD|
Call for more information